SCHEMBL2787048

SCHEMBL2787048

CN1CNc2c1nc(N)[nH]c2=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 6/20 0.50
NOS1 P29475 5/20 0.40
PNP P00491 1/20 0.40
USP2 O75604 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PAH P00439 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycidol SCHEMBL7503069 0.84 HPRT1 (0.51) HPRT1NOS1USP2CASP7HSD17B10
SCHEMBL8537089 0.80 HPRT1 (0.45) HPRT1NOS1PNPUSP2CASP7
SCHEMBL9364441 0.80 HPRT1 (0.60) HPRT1NOS1PNPUSP2CASP7
SCHEMBL20849726 0.79 HPRT1 (0.33) HPRT1
SCHEMBL3743947 0.79 HPRT1 (0.56) HPRT1NOS1USP2CASP7HSD17B10
SCHEMBL8896087 0.78 HPRT1 (0.46) HPRT1NOS1USP2CASP7HSD17B10
SCHEMBL23027363 0.77 TYMS (0.35) HPRT1
SCHEMBL21637016 0.77 HPRT1 (0.57) HPRT1NOS1PNPNOS3NOS2
SCHEMBL9583636 0.76 HPRT1 (0.44) HPRT1NOS1USP2CASP7HSD17B10
SCHEMBL9739844 0.76 HPRT1 (0.60) HPRT1NOS1PNPUSP2CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117821287-A Strain for specifically degrading 9-methylguanine and screening method thereof 安徽大学 2024-04-05 CN claimed
EP-2196222-A1 Tricarbonyl complexes of rhenium and technetium comprising amino acids as bidentate ligands and their use as radiotherapeutic chemotoxic agents. Universität Zürich (CH) 2010-06-16 EP claimed
US-20070071672-A1 Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents ALBERTO ROGER 2007-03-29 US claimed
CN-1882365-A Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents UNIV ZUERICH (CH) 2006-12-20 CN claimed
EP-1675626-A2 USE OF METAL TRICARBONYL COMPLEXES AS RADIOTHERAPEUTIC CHEMOTOXIC AGENTS Universität Zürich (CH) 2006-07-05 EP claimed
WO-2005039648-A2 USE OF METAL TRICARBONYL COMPLEXES AS RADIOTHERAPEUTIC CHEMOTOXIC AGENTS Universität Zürich (CH) 2005-05-06 WO claimed
EP-4689108-A1 SMAD7 INHIBITORY ANTISENSE OLIGONUCLEOTIDES (ASO) FOR TREATING POUCHITIS AND METHODS OF USING THE SAME Nogra Pharma Limited (IE) 2026-02-11 EP disclosed
CN-117821287-B Strain for specifically degrading 9-methylguanine and screening method thereof 安徽大学 2026-02-03 CN disclosed
CN-117821287-B Strain for specifically degrading 9-methylguanine and screening method thereof 安徽大学 2026-02-03 CN disclosed
EP-4479034-A1 CAPSAICIN DERIVATIVES AS BIOENHANCERS ON ACTIVE SUBSTANCES METABOLIZED BY CYP1A2 AND CYP2D6 aXichem AB (SE) 2024-12-25 EP disclosed
CN-119053326-A Capsaicin derivatives as bioenhancers of active substances metabolized by CYP1A2 and CYP2D6 艾克西化学公司 2024-11-29 CN disclosed
WO-2024200594-A1 SMAD7 INHIBITORY ANTISENSE OLIGONUCLEOTIDES (ASO) FOR TREATING POUCHITIS AND METHODS OF USING THE SAME NOGRA PHARMA LIMITED (IE) 2024-10-03 WO disclosed
CN-117821287-A Strain for specifically degrading 9-methylguanine and screening method thereof 安徽大学 2024-04-05 CN disclosed
US-5773424-A PARASITICIDE RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1998-06-30 US disclosed
EP-0755255-A1 TREATMENT OF TOXOPLASMOSIS UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) 1997-01-29 EP disclosed
WO-1996018398-A1 TREATMENT OF TOXOPLASMOSIS THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) 1996-06-20 WO disclosed
EP-0464112-B1 A PROCESS FOR THE PREPARATION OF 9-SUBSTITUTED GUANINE DERIVATIVES AND INTERMEDIATES FOR USE IN THE PROCESS GEA FARMACEUTISK FABRIK AS (DK) 1994-10-05 EP disclosed
US-5223619-A Catalytic cyclization A/S GEA FARMACEUTISK FABRIK (DK) 1993-06-29 US disclosed
EP-0464112-A1 A PROCESS FOR THE PREPARATION OF 9-SUBSTITUTED GUANINE DERIVATIVES AND INTERMEDIATES FOR USE IN THE PROCESS. GEA FARMACEUTISK FABRIK AS (DK) 1992-01-08 EP disclosed
WO-1990011283-A1 A PROCESS FOR THE PREPARATION OF 9-SUBSTITUTED GUANINE DERIVATIVES AND INTERMEDIATES FOR USE IN THE PROCESS A/S GEA FARMACEUTISK FABRIK (DK) 1990-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070071672-A1 Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents TOP2B, TK2, MLX HPRT1 562/4885NOS1 4363/4885PNP 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.